Christopher D Watt
Overview
Explore the profile of Christopher D Watt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
468
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bakas S, Sako C, Akbari H, Bilello M, Sotiras A, Shukla G, et al.
Sci Data
. 2022 Jul;
9(1):453.
PMID: 35906241
Glioblastoma is the most common aggressive adult brain tumor. Numerous studies have reported results from either private institutional data or publicly available datasets. However, current public datasets are limited in...
2.
Nasrallah M, Binder Z, Oldridge D, Zhao J, Lieberman D, Roth J, et al.
Acad Pathol
. 2019 Jun;
6:2374289519848353.
PMID: 31206012
Molecular profiling of glioblastoma has revealed complex cytogenetic, epigenetic, and molecular abnormalities that are necessary for diagnosis, prognosis, and treatment. Our neuro-oncology group has developed a data-driven, institutional consensus guideline...
3.
McMahon C, Canaani J, Rea B, Sargent R, Qualtieri J, Watt C, et al.
Blood Adv
. 2019 May;
3(10):1581-1585.
PMID: 31122910
No abstract available.
4.
McMahon C, Ferng T, Canaani J, Wang E, Morrissette J, Eastburn D, et al.
Cancer Discov
. 2019 May;
9(8):1050-1063.
PMID: 31088841
Gilteritinib is a potent and selective kinase inhibitor with single-agent clinical efficacy in relapsed/refractory -mutated acute myeloid leukemia (AML). In this context, however, gilteritinib is not curative, and response duration...
5.
Brown J, Beldorth I, Laosinchai-Wolf W, Fahey M, Jefferson K, Ruskin A, et al.
J Mol Diagn
. 2019 Apr;
21(4):718-733.
PMID: 31026597
This study describes the analytical performance of the QuantideX qPCR BCR-ABL IS Kit, the first Food and Drug Administration-cleared assay designed to monitor breakpoint cluster region-Abelson tyrosine-protein kinase 1 (BCR-ABL1)...
6.
Hatem J, Schrank-Hacker A, Watt C, Morrissette J, Rubin A, Kim E, et al.
Diagn Pathol
. 2016 Dec;
11(1):137.
PMID: 27993143
Background: Diffuse large B-cell lymphoma (DLBCL) typically leads to effacement of the nodal architecture by an infiltrate of malignant cells. Rarely (<1%), DLBCL can present with an interfollicular pattern (DLBCL-IF)...
7.
Hiemenz M, Kadauke S, Lieberman D, Roth D, Zhao J, Watt C, et al.
PLoS One
. 2016 Apr;
11(4):e0152851.
PMID: 27043212
Next-generation sequencing (NGS) is a powerful platform for identifying cancer mutations. Routine clinical adoption of NGS requires optimized quality control metrics to ensure accurate results. To assess the robustness of...
8.
Luskin M, Huen A, Brooks S, Stewart C, Watt C, Morrissette J, et al.
Haematologica
. 2015 Jun;
100(10):e412-4.
PMID: 26113416
No abstract available.
9.
Aggarwal C, Shi W, Watt C, Van Deerlin V, Haas A, Simone 2nd C, et al.
J Clin Oncol
. 2014 Feb;
32(30):e101-3.
PMID: 24550426
No abstract available.
10.
Frank R, Baloch Z, Gentile C, Watt C, LiVolsi V
Endocr Pathol
. 2013 Dec;
25(3):236-40.
PMID: 24337906
Multifocal fibrosing thyroiditis (MFT) is characterized by numerous foci of fibrosis in a stellate configuration with fibroelastotic and fibroblastic centers entrapping epithelial structures. MFT has been proposed as a risk...